©2024 Stanford Medicine
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Not Recruiting
Trial ID: NCT00250432,
Purpose
Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3
times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or
systemic yeast infections)
Official Title
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults
Stanford Investigator(s)
Wes (Janice) Brown
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Dora Ho
Clinical Professor, Medicine - Infectious Diseases
Eligibility
Inclusion Criteria:
- Clinical and Laboratory evidence of blood stream &/or systemic candida infections
Exclusion Criteria:
- Possible candida contamination
- Candida colonization (non invasive infection), urine, cardiac, bone or brain and
prosthetic device infections
- Acute or moderately severe liver disease
- Abnormal liver function tests
- Abnormal blood clotting for patients on blood thinners
Intervention(s):
drug: caspofungin acetate
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joanna Schaenman